Environmental demands, the evolution of care models, new delivery technologies and AI tools are influencing how medtechs must approach innovation.

ResMed’s reported a 16% rise in first-quarter fiscal year sales and 5% cut of its workforce amid restructuring of parts of its business.

This week, Illumina responded to the European Commission’s order for it to divest Grail; StrokeDX won a global innovation competition; and the US Food and Drug Administration approved expanded labeling for Boston Scientific’s WaveWriter Alpha to include painful diabetic peripheral neuropathy.

He may not be Ali, but Butterfly Network's new CEO, Joseph DeVivo, believes Butterly’s microchip tech packs a formidable punch. He expects the company’s technology will help it transcend the market-development challenges the company faced under its previous leaderships.